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Summary 
Kawasaki disease (KD) is an acute muhisystem vasculitis of unknown etiology that is associated 
with marked activation of T cells and monocyte/macrophages. Using a quantitative polymerase 
chain reaction (PCR) technique, we recently found that the acute phase of KD is associated 
with the expansion of T  cells expressing the V/32 and V/38.1 gene segments. In the present 
work, we used a newly developed anti-V/32 monoclonal antibody (mAb) and studied a new group 
of KD patients to extend our previous PCR results.  Immunofluorescence analysis confirmed 
that V/32-bearing T cells are selectively increased in patients with acute KD. The increase occurred 
primarily in the CD4 T  cell subset.  The percentages of V/32 + T  cells as determined by mAb 
reactivity and flow cytometry correlated linearly with V/3 expression as quantitated by PCR. 
However, T  cells from acute KD patients appeared to express proportionately higher levels of 
V/32 transcripts per cell as compared with healthy controls or convalescent KD patients. Sequence 
analysis of T cell receptor/3 chain genes of V/32 and V/38.1 expressing T cells from acute KD 
patients showed extensive junctional region diversity. These data showing polyclonal expansion 
of V/32 + and V/38 + T cells in acute KD provide additional insight into the immunopathogenesis 
of this disease. 
K 
awasaki disease (KD) 1 is an acute illness of early child- 
hood characterized by fever, induration, and erythema 
of the hands and feet,  inflammation of the mucous mem- 
branes, polymorphous skin rash, and cervical lymphadenop- 
athy (1, 2). As a complication of this muhisystem disease, 
coronary artery aneurysms or ectasia secondary to vasculitis 
develop in 15-25% of affected patients (3, 4). In the United 
States, KD is currently the major cause of acquired heart dis- 
ease in children. Although epidemiologic evidence strongly 
supports an infectious etiology for this disease, the causative 
agent is unknown. 
KD is associated with marked activation of T  cells and 
monocyte/macrophages, as well as increased production of 
IL-1/3, TNF-oe, and ID6 (for a review, see reference 5). The 
marked immune activation and production of cytokines are 
1 Abbreviations used in this paper: KD, Kawasaki  disease; SEB, staphylococcal 
enterotoxin B; TSST-1, toxic shock syndrome toxin 1. 
thought to play an important role in the pathogenesis of vas- 
cular endothelial cell injury during acute disease by eliciting 
proinflammatory and prothrombotic responses (6). These im- 
munologic features are characteristic of diseases that are caused 
by microbial toxins that act as superantigens to stimulate a 
large proportion of T cells expressing specific TCR/3 chain 
variable (V/3) gene segments (7). In this regard, toxic shock 
syndrome, a disease with many clinical features similar to acute 
KD, is caused by staphylococcal toxic shock syndrome toxin 
1 (TSST-1), a superantigen that induces the massive expan- 
sion, in vitro and in vivo, of V/32 + T  cells (8). 
Using a quantitative PCR technique, we recently found 
that the acute but not the convalescent phase of KD is as- 
sociated with the expansion of T cells expressing V/32 and 
V/38 gene segments (9). In contrast, the T cell repertoire in 
patients with other febrile illnesses and exanthems did not 
undergo similar alterations (9). These observations suggested 
that the T cell activation associated with KD is due to super- 
antigenic stimulation. An important characteristic  of such 
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JB, Vow, Jo~) of the TCR are not generally involved in an- 
tigen recognition (7). The present study was therefore car- 
fled out to characterize the TCRjunctional diversity associated 
with the expansion of V~2 and V/~8 T  cells during acute 
KD and to use a newly available anti-V~2 mAb to extend 
our previous  PCR studies. 
Materials and Methods 
Patients.  23 patients  with KD (mean age, 38 too; range, 10 mo-7 
yr, 6 mo) were studied. The flow cytometry studies were done on 
20 new KD patients, not previously reported on, whereas the 
cloning and sequencing of TCK ~ chain junctional regions were 
carried out on three Vfl2 amplified gene products obtained from 
three patients previously  studied (9). The latter three samples were 
selected for their particularly high level of VB2 expression (see 
below). Acute KD was defined  by the diagnostic guidelines of the 
American Heart Association (10) and required that patients have 
no clinical and/or laboratory evidence of any other disease known 
to mimic KD. Blood was drawn before  intravenous  gamma globulin 
treatment in 18 patients with acute KD (within 10 d of the onset 
of fever) and after 30 d of the onset of fever in 10 patients (convales- 
cent KD). We were able to obtain eight paired samples from the 
acute and convalescent  phase of KD. 13 children and 8 adults were 
studied as healthy controls. Because the highest prevalence of KD 
is seen in Japan, and 6 out of 23 of the KD patients in our study 
were Japanese, we included six Japanese children and four Japanese 
adults in the healthy control group although our previous study 
showed that ethnic differences  did not affect the TCK repertoire 
(9). Informed consent was obtained from either the patient or the 
child's parents according to the guidelines of each medical center. 
Lymphocyte Isolation and Culture.  PBMC were isolated from 
heparinized blood by Ficoll-Hypaque density gradient centrifuga- 
tion. PBMC were then analyzed either fresh or after culture with 
anti-CD3 and IL-2 to increase the production of functional TCR 
mlLNA for the TCIL VB analysis  by PCR. In these experiments, 
PBMC were stimulated for 3 d at 37~  with anti-CD3 (20 ng/ml; 
Ortho Diagnostic Systems  Inc., Westwood, MA), washed and ex- 
panded for 1 d in Ib2 as previously  described (8, 9). Previous studies 
with cells from normal individuals have demonstrated that anti- 
CD3 stimulation for 3 d does not selectively  expand a particular 
V/3 population compared with freshly isolated PBMC (8, 9). 
Assessment of TCR V•  Expression.  We used two methods to 
assess the TCR VB repertoire in peripheral blood. The first method 
utilized two-color immunofluorescence with biotinylated mAbs 
directed at four different  V~ segments as previously  described (11). 
These included mAbs directed to Vfl2 (clone  E22E7; Immunotech, 
Marseille, France), VB5.1 (clone LC4; T Cell Science, Cambridge, 
MA). V/~8.1;8.2 (clone MX6, [12]), and V/312 (clone $511, [13]), 
followed  by incubation with streptavidin-PE  (1:100) (Fisher  Biotech, 
Pittsburgh, PA) and FITC-conjugated  anti-CD3, anti-CD4, or anti- 
CD8 (Olympus Corp., Lake  Success, NY). The anti-V32 antibody 
(routine IgM) was produced by using spleen cells from mice im- 
munized with a murine TCR 3 chain-defirient hybridoma that 
had been transfected with a human-routine chimeric hV32-hDJfl- 
hC3-mCfl DNA construct (Romagne, F., L. Besnardeau, and B. 
Malissen, manuscript in preparation). Its specificity  was confirmed 
by showing that it stained T cell hybridomas expressing  hVB2, but 
not hybridomas expressing other human V/~s, as well as human 
T cell  clones  expressing  VB2, but not human T cell  clones  expressing 
members of other VB families. The V~ expression of the latter 
T cell hybridomas and clones were independently determined by 
PCR (14). In accord with quantitative PCR results (14), the blast 
population after in vitro stimulation with TSST-1 was greatly en- 
riched for cells staining with E22E7 (>50% vs >10% staining in 
the starting population), whereas cells staining with this mAb were 
excluded from blasts after stimulation with staphylococcal en- 
terotoxin B (SEB). Fluorescence intensity was analyzed with an 
Epics Profile Cytofluorograph (Coulter Electronics Inc., Hialeah, 
FL). Both freshly  isolated and cultured PBMC were analyzed.  For- 
ward angle and 90  ~ light-scatter patterns were used to gate on lym- 
phocytes or blast cells  in each  case. The percentage of  T cells  bearing 
each TCR VB phenotype was expressed as a percentage of total 
T (CD3 +) cells. 
The second  method utilized a quantitative PCR method to esti- 
mate the proportion of T cells expressing particular VB gene seg- 
ments (14). In these experiments, 2/zg of total RNA prepared from 
anti-CD3-stimulated cells  was used for the synthesis  of first-strand 
cDNA.  For  each PCR,  TCk  3  and  a  chain cDNAs  were 
coamplified  using oligonucleotide  primers specific  for V~2 or Vfll2 
and an oligomer  from the downstream/3  chain C region (C~ primer) 
as one pair, and two Ca primers as the other pair. The sequences 
of the specific  primers used and details of the PCIL have  been pub- 
lished (14). The amount of product was quantitated by incorpora- 
tion of 32p end-labeled 3' primers added to the reactions (~106 
cpm each). The data were expressed as amount of  V3 product over 
the amount of Ca product, or VjffCa ratio, for each Vfl. The 
PCR technique employed 23 cycles of amplification. In separate 
experiments, we analyzed  the quantitative nature of the PCIL tech- 
nique by examining input Vfl RNA versus amount of amplified 
PCR product obtained. Over the range of V~ values obtained in 
this study, there was a direct linear correlation between the ratio 
of  V3 PCR product amplified  and the amount of mRNA analyzed. 
Cloning and Sequencing of TCR ,8 Chain  Junctional Regions.  10 
/xg of total RNA was used to synthesize cDNA followed  by PC1L 
with a Vfl2 or Vfl8.1 primer and a 3' C3 primer. The sequences 
of the primers were 5'-GGGAATTCTCATCAACCATGCAAG- 
CCTGACCT-3' for Vfl2, 5'-GGGAATTCATTTACTTTAACAA- 
CAACGTTCCG-3' for Vfl8.1, and 5'-GGGATCCTTCTGATGG- 
CTCAAACAC-3' for C~. The Vfl and Cfl primers carried EcoRI 
or BamHI sites, respectively  (underlined). After 22 cycles  of PCR, 
amplified/3  chain fragments  were extracted  with phenol-chloroform 
and precipitated  with ethanol. Purified  fragments  were then digested 
with EcoRI and BamHI, ligated into plasmid pTZ18R (Pharmacia 
LKB Biotechnology Inc., Piscataway, NJ) and cloned. Double- 
stranded plasmid DNAs were prepared by alkali-lysis  method and 
acid phenol extraction and were sequenced by Sequenase Ver2.0 
kit (US Biochemical,  Cleveland,  OH) following the manufacturer's 
recommendations (15). 
Results and Discussion 
In a previous study using a quantitative PCR technique 
and 22 different V~/-spedfic primers, we reported markedly 
increased expression  of VB2 and less so of VB8.1  gene seg- 
ments by peripheral blood T  cells from acute KD patients 
(9).  A mAb to VB2 was not available at the time of those 
analyses, but has since been generated. In the following ex- 
periments, we analyzed TCK V32 expression  using a VB2- 
specific mAb and flow cytometry and compared these data 
to results obtained with the quantitative PCR technique on 
samples from a new group of KD patients. All cells in these 
experiments were initially stimulated with anti-CD3. 
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Figure  1.  V/~2  +  T  cells are  increased  during  the  acute  phase  of 
Kawasaki disease. PBMC were stimulated  with anti-CD3 and Ib2 and 
analyzed by immunofluorescence and flow cytometry with anti-VB2 and 
VB5.1 mAbs. Bars, mean  _+  SEM. 
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Figure 3.  Freshly isolated PBMC from acute KD patients (filled bars) 
and healthy controls (open  bars) were analyzed  by two-color immunofluores- 
cence with biotinylated anti-V~ mAbs and FITC-conjugated  anti-CD3, 
CD4, and CD8. Data represent the mean  _+  SEM. 
As shown in Fig. 1, the mean percentage of V/~2 + T  cells 
in  13 acute KD patients  was significantly higher  than  the 
control group of 13 healthy children (mean  _+  SEM  =  8.1 
+  0.5% for acute KD vs. 6.4  +_ 0.3% for healthy children; 
p  =  0.01 by two tailed unpaired Student's t test),  or eight 
healthy adults (5.7  _+  0.5% for healthy adults; p  =  0.007). 
In contrast,  there was no significant  difference seen in the 
percentages of T  cells bearing VJ55.1 between patients  (2.9 
+  0.2%) and controls (2.6  +  0.3%; p  =  0.22). The mean 
percentage of V~2 + T  cells in acute KD patients  was also 
increased compared with convalescent KD patients  (6.2  _ 
0.6%; p  =  0.03). A decrease in V/~2 § T cells after the acute 
phase was also apparent in the eight patients followed seri- 
ally (Fig.  1). Only one patient maintained  an increased per- 
centage of VB2 + T  cells  in convalescence.  It is interesting 
that this patient developed mitral valve insufficiency as a com- 
plication of her KD.  None of the other patients  studied in 
convalescence showed signs  of cardiac involvement. 
We also analyzed the ratio of V~ cDNA to Cc~ cDNA 
amplified by PCR using the same PBMC that were studied 
by immunofluorescence analysis. We analyzed V/~2/Ccz and 
VB12/C(x ratios of samples from both acute and convales- 
cent KD patients and control subjects. To obtain a wide range 
for V~12 expression,  some of the control PBMC were also 
stimulated  with  SEB  (11) and  analyzed  by  both  im- 
munofluorescence and PCR. The VB/Cot ratios obtained by 
PCR were compared with the percentages of T cells bearing 
a particular  VB as determined by immunofluorescence.  A linear 
correlation was found between these two methods of V/~ anal- 
ysis (Fig.  2).  In healthy controls and convalescent KD pa- 
Figure 2.  Correlation between VB expression as determined by immunofluorescence and by PCK. TCK VB expression in anti-CD3 activated T 
cells from patients with acute KD (e), convalescent KD (O), and healthy controls (A) as well as SEB-stimulated T cells from healthy controls (A) 
was determined by both VB-speeific  mAbs and quantitative PCK. Cytofluorographic data are presented as the percentage of total cells staining  positive, 
and PCR data are expressed as the ratio of the amount of labeled primers incorporated  into the V~ and Cox bands, i.e., the VB/C~x ratio.  (Shaded 
areas) Mean  _+  2 SD for both percentage of cells staining and VB/Ccx ratios determined for a group of healthy controls.  Results are shown for V~2 
(left) and VB12 (right). 
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Junctional sequence  Junctional sequence 





CSAR  DREQGF  NEKL  (1.4)  KD5  CSA  KYR.GLS  TEAF  (1.1) 
CSAR  DRTV  NEKL  (1.4)  (V/~2)  CSA  PSRDRGRK  TEAF  (1.1) 
CSAR  GG  NQPQH  (1.5)  CSA  YREM  NTEAF  (1.1) 
CSA  RLGTGA  NEQF  (2.1)  CSA  YRAMT  YGYT  (1.2) 
CSAR  ALAGD  EQF  (2.1)  CSA  PRDDLPQA  YGYT  (1.2) 
CSA  SGR.LSY  NEQF  (2.1)  CSA  TDRVK  NTIY  (1.3) 
CSAR  QR  SYNEQF  (2.1)  CSA  GTGT  YNEQF  (2.1) 
CSA  LPELWREGD  TGELF  (2.2)  CSAR  HPRAY  EQF  (2.1) 
CSA  PGA  TGELF  (2.2)  CSA  SREGSS  ETQY  (2.5) 
CSAR  DPR  GELF  (2.2)  CSA  SGQV  QETQY  (2.5) 
CSA  SYPI  STDTQY  (2.3)  CSA  KKTGAL  ETQY  (2.5) 
CS  P,  NTLGR  TDTQY  (2.3)  CSA  KPGH  QETQY  (2.5) 
CSA  DRG  TDTQY  (2.3)  CSA  SQGGL  YEQY  (2.7) 
CSA  KLAGAA  DTQY  (2.3)  CSAK  DQTSP,.V  YEQY  (2.7) 
CS  VFDRE  Y  (2.4)  CSA  GLT  SYEQY  (2.7) 
CSA  ARGMQ  NIQY  (2.4)  CS  GIGT  SYEQY  (2.7) 
CSA  TYAGKD  EQY  (2.7)  CSAR  DVFGERVG  EQY  (2.7) 
CSA  SIGAKT  YEQY  (2.7)  CSAR  GAVGD  SYEQY  (2.7) 
CSA  TPSSGNL  YEQY  (2.7) 
CSAR  DVLSPS  EKL  (1.4)  KD 3  CASS  PGTA  EAF  (1.1) 
CSAP,  DWGA  NQPQH  (1.5)  (VBS)  CASS  PTGN  TEAF  (1.1) 
CSA  TSTGAGP  PLH  (1.6)  CAS  EDSAS  NYGYT  (1.2) 
CSA  RGGSDVRW  NEQF  (2.1)  CASS  FGQQ  NQPQH  (1.5) 
CSA  SGRAT  YNEQF  (2.1)  CASS  LVG  PQH  (1.5) 
CSA  SGF  YNEQF  (2.1)  CASS  PQRIGQA  QPQH  (1.5) 
cs  GP,  SWGGSN  NEQF  (2.1)  CAS  KPGD  SPLH  (1.6) 
CSA  GGLAG  TGELF  (2.2)  CAS  RTAGAF  NEQF  (2.1) 
CS  VPLWGPHWG  TDTQY  (2.3)  CASS  LAGGN  NEQF  (2.1) 
CSA  WTSGSS  TDTQY  (2.3)  CAS  TSPGAT  YNEQF  (2.1) 
CSAR  DTDK  DTQY  (2.3)  CAS  TWLGV  NEQF  (2.1) 
CSAR  GWTSGKG  ETQY  (2.5)  CASS  RDTGD  GELF  (2.2) 
CSAR  QY  QETQY  (2.5)  CAS  SFHEG  ETQY  (2.5) 
CSAP,  WTSPFS  SYEQY  (2.7)  CASS  TSGG  QY  (2.7) 
CASS  HKS  EQY  (2.7) 
CASS  TQRKDE  YEQY  (2.7) 
The VB2/C~x ratio was 0.26 for donor KD3, 0.29 for KD4, and 0.46 for donor KD5 as compared to a mean VB2/Ccz ratio of 0.10 for normals. 
The VBS/C~x ratio was 0.14 for KD3 as compared to a mean VBS/Ccx ratio of 0.07 for normals. Three clones that contained stop codons and 
two KD4 clones, one containing  J31.4 and the other J/~2.7, that could not be defined  in the junctional region, are not shown. 
tients, the slopes of the regression lines for V32 and V312 
had similar values of 0.01 and 0.02, respectively, indicating 
that the VB fragments were amplified by PCR with similar 
ef~dencies.  It is interesting that in acute KD  patients,  a 
significantly steeper slope for VB2 (0.06; p  =  0.003 by anal- 
ysis of covariance) was seen. These data suggest that in addi- 
tion to an increased percentage of V/~2 + T  cells,  there was 
proportionately greater V32 mRNA expressed per cell during 
acute KD. It is surprising that this increased expression  per 
cell appears to be maintained despite in vitro activation with 
anti-CD3 and 11.-2. 
To determine whether the in vitro anti-CD3 activation had 
794  T Cell Repertoire Changes in Acute Kawasaki  Disease an effect on the V/3 analyses, and to determine what T cell 
subsets were expanded in KD, freshly isolated PBMC taken 
from nine patients with acute KD and 11 controls were as- 
sessed for expression of V/32, 5.1, or 8.1 on CD3, CD4, and 
CD8 T  cells by direct two-color immunofluorescence  and 
flow cytometry (Fig. 3).  In the total  T  cell population, 
V/32 + and V/38.1 + cells were significantly increased in pa- 
tients with acute KD (p =  0.009 and 0.01, respectively) but 
V/35.1 + cells were not increased (p  =  0.9).  These data are 
consistent with the above data and our previous report (9). 
Although V/32  § and V/38.1 + T calls were increased in both 
CD4 and CD8 T cells in patients,  V/32 expression in only 
the CD4 population was significantly different (p  =  0.03) 
between patients  and controls. 
Superantigens stimulate T cells almost solely through the 
V/3 portion of the TCK and therefore induce an expansion 
of T cells mostly independent of their TCRjunctional regions. 
This is markedly different from T cells activated by most con- 
ventional peptide antigens which frequently results in an ex- 
pansion of only a subset of V3-expressing cells with limited 
TCK junctional diversity. To determine whether V/32  + and 
V/38 § T cells were expanded in a polyclonal vs. oligoclonal 
manner in acute KD, we analyzed the sequence of random 
eDNA clones containing PCR-amplified V/32 and V/38 seg- 
ments (Table 1). 
The sensitivity of our analysis for clonotypic expansion 
was  initially  determined by mixing normal PBMC  with 
V/38.1 + Jurkat cells. Analysis of TCR V/38.1 usage by flow 
cytometry showed that the addition of  Jurkat ceils increased 
the percentage  of CD3+/V/38 +  cells from  2.4%  in  the 
original PBMC sample to 4.8%. The V/38/CoL ratio assessed 
by PCK also increased from a baseline of 0.09 to 0.14, which 
was equal to the V/38/Cot ratio of acute KD sample no. 3 
examined simultaneously (Table 1). Sequencing  random eDNA 
clones containing PCR-amplified V/38.1 gene segments from 
the Jurkat-PBMC control mixture showed that 4 out of 10 
eDNA clones (40%) encoded the same junctional sequence 
as Jurkat clones, proportional to the immunofluorescence  data. 
These data indicated that our assay was sufficiently sensitive 
to detect oligoclonal expansions among samples with elevated 
V3/Co~ ratios  over the range of KD samples studied. 
45 V/32 eDNA clones derived from three patients  with 
acute KD who had a two- to threefold increase in V/32 gene 
expression, and 17 V/38.1 eDNA clones from a patient with 
a 60% increase in V/38 gene expression were sequenced. If 
acute KD were associated with a clonotypic expansion of 
V/32 + and  V/38  + T  cells, a significant percentage  of the 
clones could have been expected to have identical junctional 
sequences. However, as shown in Table 1, none of the V/32 
or V/38 clones had the same  junctional sequence, and consid- 
erable diversity among the sequences within each individual 
was apparent. The CDK3 regions varied greatly in terms of 
residue number and sequence. The high proportion of charged 
residues in the junctional regions is similar to other T cell 
populations  analyzed (16, 17), and a conserved motif is not 
apparent. In some sequence sets, preferential usage of certain 
J/3s (e.g., J/32.7 in patient KDS) may be suggested.  How- 
ever, this may represent a sampling artifact and similar results 
have been seen with normal samples (16). 
In view of the selective expansion of V/32  + and V/38  + T 
cells in acute KD (9), the extensive/3 chain junctional diver- 
sity suggests that these V/3s play a dominant role in recogni- 
tion. This type of  recognition is not characteristic of  responses 
to most peptide antigens.  A complex response to multiple 
antigens or epitopes also seems unlikely since multiple V/3 
regions would be expected to be involved. A dominant role 
for V/3 (vs. CDK3 region) has been occasionally observed 
for T cell responses to particular peptide-MHC complexes 
(17-19),  including a human CD4 +  T  call response  to  a 
tetanus toxin-derived peptide being presented by different class 
II MHC molecules (17). However, the apparent  frequency 
of responding cells in the circulation  of acute KD patients 
(>1 in 50) seems out-of-proportion to that expected for a 
response to a conventional antigen. Together, this high fre- 
quency of response and the prominent role for V/3 appear 
to be more consistent with the hypothesis that T cell activa- 
tion during the acute phase of KD is mediated by a superan- 
tigen. Verification that KD is caused by a superantigen awaits 
identification  of the etiologic  agent. 
The mechanism by which marked T cell activation might 
contribute to the clinical manifestations of KD is unclear. 
Bacterial superantigens  such as staphylococcal enterotoxins 
and streptococcal erythrogenic toxins (SPEs) can cause mas- 
sive T cell stimulation and cytokine release, including potent 
induction of Ibl  and TNF.  In recent studies of a murine 
modal of toxic shock syndrome, the in vivo release of TNF-oe 
was shown to be dependent on superantigen stimulation of 
T cells (20, 21). As in toxic shock syndrome, T cell stimula- 
tion may be critical to cytokine release in acute KD.  The 
production of increased circulating  levels of Ibl  and TNF 
as well as other cytokines, e.g., IL-6, have been reported to 
occur during the acute phase of KD (5). These cytokines play 
a critical role in the induction of inflammatory and throm- 
botic responses (6). In the case of acute KD, the secretion 
of Ibl and TNF is associated with the expression of leuko- 
cyte adhesion molecules which localize inflammatory cells 
to the vascular wall and are thought to play an important 
role in the pathogenesis  of vasculitis in this disease (22). 
The etiologic agent which causes KD is currently unknown. 
Nevertheless, it is widely believed that KD is caused by an 
infectious agent because of the acute self-limited nature of 
this disease, geographical clustering  of outbreaks,  the clin- 
ical symptoms of fever and exanthem mimicking other infec- 
tious diseases, and the unique susceptibility of young chil- 
dren, suggesting that humoral immunity to the KD agent 
develops early in life (23). Our present results may provide 
a new avenue of investigation into the potential etiology of 
this fascinating disease. 
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